simvastatin has been researched along with osteoprotegerin in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 10 (71.43) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Chihara, K; Kaji, H; Kanatani, M; Sugimoto, T | 1 |
| Celińska-Löwenhoff, M; Gluszko, P; Löwenhoff, T; Undas, A | 1 |
| Dollerup, J; Gormsen, LC; Mogensen, CE; Nellemann, B; Nielsen, S; Rasmussen, LM; Schmitz, O | 1 |
| Chen, C; Chen, Y; Han, G; Hou, J; Liu, C; Meng, W; Zhuang, J | 1 |
| Liu, ST; Liu, ZH; Lu, ZS; Sun, HC; Xiaohui, RF; Zong, XM | 1 |
| Dean, IN; Rawal, SY; Stein, SH; Tipton, DA | 1 |
| Andrukhov, O; Bertl, K; Liu, S; Liu, ZH; Rausch-Fan, X; Sun, H | 1 |
| Brito, GA; Dalcico, R; de Menezes, AM; Deocleciano, OB; Oriá, RB; Ribeiro, RA; Vale, ML | 1 |
| Khademi, A; Shadmehr, E | 1 |
| Bravo, M; Magán-Fernández, A; Marfil-Álvarez, R; Mesa, F; Papay-Ramírez, L; Rizzo, M; Tomás, J | 1 |
| Bauer, I; Bertolotto, M; Dallegri, F; Fabre, M; Galan, K; Lenglet, S; Mach, F; Montecucco, F; Nencioni, A; Palombo, D; Pane, B; Pelli, G; Pende, A; Python, M; Quercioli, A; Spinella, G; Vuilleumier, N | 1 |
| Brinchmann, JE; Haugen, HJ; Ostrup, E; Pullisaar, H; Reseland, JE | 1 |
| Amin, RM; El-Khatib, AS; Elmazar, MM; Khattab, MM; Raafat, SN | 1 |
| Abdollahi Kordkandi, S; Babaheidarian, P; Hajializade, M; Mirzaei, A; Moghtadaei, M; Pazoki-Toroudi, H; Yeganeh, A | 1 |
2 trial(s) available for simvastatin and osteoprotegerin
| Article | Year |
|---|---|
Effects of hypolipemic drugs on the osteoprotegerin - sRANKL system in patients with coronary artery disease.
Topics: Bone Density; Coronary Artery Disease; Double-Blind Method; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Middle Aged; Osteoprotegerin; RANK Ligand; Simvastatin; Solubility | 2007 |
Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria.
Topics: Albuminuria; Atherosclerosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Osteoprotegerin; Simvastatin | 2007 |
12 other study(ies) available for simvastatin and osteoprotegerin
| Article | Year |
|---|---|
Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures.
Topics: Animals; Bone Resorption; Calcitriol; Carrier Proteins; Cell Differentiation; Cells, Cultured; Glycoproteins; Lovastatin; Membrane Glycoproteins; Mice; Mice, Inbred ICR; Osteoclasts; Osteogenesis; Osteoprotegerin; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; RNA, Messenger; Simvastatin | 2005 |
Effects of simvastatin on relapse and remodeling of periodontal tissues after tooth movement in rats.
Topics: Alveolar Process; Animals; Bone Density Conservation Agents; Bone Remodeling; Fibroblasts; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mandible; Models, Dental; Molar; Orthodontic Wires; Osteoblasts; Osteoclasts; Osteogenesis; Osteoprotegerin; Periodontal Ligament; Periodontium; Random Allocation; RANK Ligand; Rats; Rats, Wistar; Recurrence; Simvastatin; Stress, Mechanical; Time Factors; Tooth Movement Techniques | 2010 |
[Effect of simvastatin on the function of MG63 cell line].
Topics: Bone Regeneration; Cell Line; Cell Proliferation; Humans; Osteoblasts; Osteocalcin; Osteoprotegerin; Simvastatin | 2010 |
Statins regulate interleukin-1β-induced RANKL and osteoprotegerin production by human gingival fibroblasts.
Topics: Atorvastatin; Cell Culture Techniques; Cell Survival; Cells, Cultured; Coloring Agents; Culture Media, Serum-Free; Fibroblasts; Gingiva; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-1beta; Osteoprotegerin; Pyrroles; RANK Ligand; Simvastatin; Temperature; Tetrazolium Salts; Thiazoles; Time Factors | 2011 |
Effect of simvastatin on the osteogenetic behavior of alveolar osteoblasts and periodontal ligament cells.
Topics: Adult; Alkaline Phosphatase; Alveolar Process; Anticholesteremic Agents; Bone Regeneration; Cell Survival; Cells, Cultured; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Osteoblasts; Osteocalcin; Osteogenesis; Osteoprotegerin; Periodontal Ligament; RANK Ligand; Simvastatin; Time Factors | 2012 |
Protective mechanisms of simvastatin in experimental periodontal disease.
Topics: Alanine Transaminase; Alkaline Phosphatase; Alveolar Bone Loss; Animals; Anti-Inflammatory Agents; Antioxidants; Aspartate Aminotransferases; Bone Morphogenetic Protein 2; Female; Gingiva; Glutathione; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-10; Interleukin-1beta; Malondialdehyde; Matrix Metalloproteinase 1; Matrix Metalloproteinase 8; Nitrates; Nitric Oxide Synthase Type II; Nitrites; Osteoprotegerin; Oxidative Stress; Periodontitis; Peroxidase; RANK Ligand; Rats; Rats, Wistar; Receptor Activator of Nuclear Factor-kappa B; Simvastatin; Tumor Necrosis Factor-alpha | 2013 |
Effect of simvastatin on kinetics of osteoprotegrin/receptor activator nuclear kappa B Ligand mRNA expression in periapical lesions.
Topics: Animals; Kinetics; Ligands; Male; Osteoprotegerin; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; RNA, Messenger; Simvastatin | 2013 |
Association of simvastatin and hyperlipidemia with periodontal status and bone metabolism markers.
Topics: Adult; Aged; Alcohol Drinking; Biomarkers; Blood Sedimentation; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Collagen Type I; Cross-Sectional Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Osteocalcin; Osteoprotegerin; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Procollagen; Simvastatin; Smoking; Triglycerides | 2014 |
Statin treatment is associated with reduction in serum levels of receptor activator of NF-κB ligand and neutrophil activation in patients with severe carotid stenosis.
Topics: Aged; Atherosclerosis; Atorvastatin; Carotid Stenosis; Cohort Studies; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Matrix Metalloproteinase 9; Middle Aged; Neutrophil Activation; Neutrophils; NF-kappa B; Osteopontin; Osteoprotegerin; Pyrimidines; Pyrroles; RANK Ligand; Risk Factors; RNA, Messenger; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2014 |
Simvastatin coating of TiO₂ scaffold induces osteogenic differentiation of human adipose tissue-derived mesenchymal stem cells.
Topics: Adipose Tissue; Adult; Cell Differentiation; Cell Survival; Collagen Type I, alpha 1 Chain; Female; Humans; Mesenchymal Stem Cells; Middle Aged; Osteocalcin; Osteogenesis; Osteopontin; Osteoprotegerin; RNA, Messenger; Simvastatin; Tissue Engineering; Tissue Scaffolds; Titanium; Vascular Endothelial Growth Factor A | 2014 |
The sole and combined effect of simvastatin and platelet rich fibrin as a filling material in induced bone defect in tibia of albino rats.
Topics: Alkaline Phosphatase; Animals; Bone Morphogenetic Protein 2; Humans; Male; Osteocalcin; Osteoprotegerin; Platelet-Rich Fibrin; RANK Ligand; Rats; Simvastatin; Tibia; Vascular Endothelial Growth Factor A | 2018 |
Significant effect of simvastatin and/or ezetimibe-loaded nanofibers on the healing of femoral defect: An experimental study.
Topics: Animals; Bone Density; Ezetimibe; Femur; Fracture Healing; Male; Nanofibers; Osteoprotegerin; Rats, Wistar; Simvastatin | 2020 |